- |||||||||| alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Enrollment closed, Enrollment change, Trial primary completion date: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - Sep 19, 2018 P1, N=42, Active, not recruiting, Completed --> Terminated Completed --> Active, not recruiting | N=26 --> 42 | Trial primary completion date: Apr 2018 --> Oct 2018
- |||||||||| cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial completion, Enrollment change, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Aug 31, 2018 P2, N=142, Completed, Completed --> Active, not recruiting | N=26 --> 42 | Trial primary completion date: Apr 2018 --> Oct 2018 Active, not recruiting --> Completed | N=92 --> 142
- |||||||||| Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 29, 2018 P2, N=42, Completed, Trial completion date: Dec 2020 --> Feb 2018 | Active, not recruiting --> Terminated; Low accrual Active, not recruiting --> Completed
- |||||||||| Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial completion, Enrollment change, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Apr 11, 2018 P1, N=34, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | N=60 --> 34
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells (clinicaltrials.gov) - Jan 24, 2018 P2, N=20, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion, Enrollment change, Post-transplantation: Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Jan 2, 2018 P2, N=63, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | N=100 --> 63
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Phase classification: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (clinicaltrials.gov) - Nov 17, 2017 P1, N=4, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2018 Phase classification: P=N/A --> P1
- |||||||||| Gliadel Wafer (carmustine implant) / Eisai, Azurity Pharma, Rituxan (rituximab) / Roche
Trial completion: Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Oct 3, 2017 P2, N=68, Completed, Phase classification: P=N/A --> P1 Active, not recruiting --> Completed
- |||||||||| Zolinza (vorinostat) / Merck (MSD)
Trial primary completion date: COMBOSTAT: Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (clinicaltrials.gov) - Sep 19, 2017 P2, N=0, Withdrawn, Active, not recruiting --> Completed | N=60 --> 17 | Trial primary completion date: Dec 2016 --> Nov 2012 Trial primary completion date: Apr 2014 --> May 2012
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (clinicaltrials.gov) - Jul 17, 2017 P=N/A, N=4, Completed, Active, not recruiting --> Completed | N=40 --> 29 Active, not recruiting --> Completed | N=12 --> 4 | Trial primary completion date: Jan 2017 --> Aug 2016
- |||||||||| denintuzumab mafodotin (SGN-CD19A) / Seagen
Trial completion, Trial primary completion date: A Safety Study of SGN-CD19A for Leukemia and Lymphoma (clinicaltrials.gov) - Jul 2, 2017 P1, N=92, Completed, Active, not recruiting --> Completed | N=12 --> 4 | Trial primary completion date: Jan 2017 --> Aug 2016 Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> May 2017
- |||||||||| denintuzumab mafodotin (SGN-CD19A) / Pfizer
Trial completion: A Safety Study of SGN-CD19A for B-Cell Lymphoma (clinicaltrials.gov) - Jul 2, 2017 P1, N=64, Completed, Active, not recruiting --> Completed | Trial primary completion date: Feb 2018 --> May 2017 Active, not recruiting --> Completed
- |||||||||| Biomarker, Trial completion, Trial primary completion date: Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 17, 2017
P=N/A, N=186, Completed, Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017 Not yet recruiting --> Completed | Trial primary completion date: Mar 2013 --> Feb 2012
|